Nuvation cancels plans to test brain cancer drug directly against Voranigo on FDA’s advice
Nuvation Bio has backed off from its plans to directly compare its brain cancer drug to Servier’s Voranigo, instead opting to focus on patients who aren’t covered by the approved…